143
Manuscript.docx
Manuscript_Submission_Checklist_and_Author_Declaration.pdf
Cover letter.pdf
Manuscript+12-04-2025 (1).docx
3- AJID OA Olfatifar Jan 2026 RTG.docx
3- AJID OA Olfatifar Jan 2026 RTG.pdf
3- AJID OA Olfatifar Jan 2026 RTG.pdf
146
10.60141/ajid.143
Trends the Future Burden of Visceral Leishmaniasis in Afghanistan, Iran, and Pakistan: A Regional Epidemiological Modeling Study
<p><strong>Background:</strong> Visceral leishmaniasis (VL) remains one of the world’s most severe neglected tropical diseases, causing substantial morbidity and mortality in low-resource settings. Despite regional control efforts, the disease persists as a major health challenge in the Middle East and South Asia. We aimed to estimate and forecast the sex-specific and national burden of VL in three neighboring countries of Afghanistan, Iran, and Pakistan through 2040.</p>
<p><strong>Methods:</strong> To estimate the future prevalence of VL we applied an illness–death model using sex-specific data from the Global Burden of Disease 2021. Historical data from 1990–2021 were used to calibrate the model and forecast national trajectories of VL prevalence to 2040.</p>
<p><strong>Results:</strong> In 2023, Afghanistan had the highest age-standardized VL prevalence (0.0176), followed by Iran (0.0159) and Pakistan (0.0093). Projections indicate strikingly divergent trends by 2040: prevalence is expected to rise to 0.045 (95% CI: 0.03–0.08) in Afghanistan and 0.211 (95% CI 0.10–0.45) in Pakistan representing increases of 156% and over 2,100%, respectively while Iran is projected to experience a sustained decline to 0.002 (95% CI: 0–0), an 87% reduction compared with 2021. These patterns are consistent across both sexes, though male prevalence remains roughly twice that of females.</p>
<p><strong>Conclusion:</strong> Afghanistan’s decline likely reflects under-detection due to health system fragility, while Pakistan’s surge may result from both improved surveillance and genuine spread. Iran’s continued reduction demonstrates the impact of sustained public health investment. Strengthening surveillance and incorporating health system indicators into predictive models are crucial for accurate projections and effective regional control.</p>
https://creativecommons.org/licenses/by/4.0
Meysam Olfatifar , Milad Badri
2026
Leishmaniasis
Neglected tropical disease
Disease burden
Epidemiology
Meysam
Olfatifar
Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran
IR
ol.meysam92@gmail.com
Milad
Badri
Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
IR
Badri22.milad@gmail.com
176
PDF
0
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog. 2013;9(1):e1003053.
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–70.
Organization WH. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organization; 2022.
Elnaiem DEA. Ecology and control of the sand fly vectors of Leishmania donovani in East Africa, with special emphasis on Phlebotomus orientalis. J Vector Ecol. 2011;36:S23--S31.
Wamai RG, Kahn J, McGloin J, Ziaggi G. Visceral leishmaniasis: a global overview. J Glob Heal Sci. 2020;2(1).
Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008;2(10):e313.
Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis. 2007;1(2):e114.
Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet. 2010;375(9710):239–47.
Saeed KMI, Tamim MS, Hakim MS, Naeemi S, Shirindil AR, Noori L, et al. Visceral Leishmaniasis in Afghanistan: Analysis of Cases from 2018 to 2022. Afghanistan J Infect Dis. 2025;3(2):156–65.
Institute Ramón y Cajal de Investigación Sanitaria. Leishmaniasis country profile – Afghanistan. Leishinfo WHO-CC55. 2022.
Mohebali M, Edrissian G, Akhoundi B, Shirzadi M, Hassanpour G, Behkar A, Rassi Y, Hajjaran H, Keshavarz H, Gouya MM, Arshi S. Visceral leishmaniasis in Iran: An update on epidemiological features from 2013 to 2022. Iran. J. Parasitol. 2023 Jul;18(3):279.
Rab MA, Iqbal J, Azmi FH, Munir MA, Saleem M. Visceral leishmaniasis: a seroepidemiological study of 289 children from endemic foci in Azad Jammu and Kashmir by indirect fluorescent antibody technique. J Pak Med Assoc. 1989;39(9):225–8.
Khan K, Khan NH, Wahid S. Systematic review of leishmaniasis in Pakistan: Evaluating spatial distribution and risk factors. J Parasitol. 2021;107(4):630–8.
Brinks R, Landwehr S. Age-and time-dependent model of the prevalence of non-communicable diseases and application to dementia in Germany. Theor Popul Biol. 2014;92:62–8.
Ito C, Kurth T, Baune BT, Brinks R. Illness-death model as a framework for chronic disease burden projection: application to mental health epidemiology. Front Epidemiol. 2022;2:903652.
4
1
2026
Fourth Volume, First issue, January 2026
24-30